Overview

Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis

Status:
COMPLETED
Trial end date:
2024-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients undergoing maintenance hemodialysis with chronic kidney disease and anemiawho are receiving stable treatment with erythropoietic stimulants (ESAs).
Phase:
PHASE3
Details
Lead Sponsor:
Shenzhen Salubris Pharmaceuticals Co., Ltd.